SCHEMBL4295771

SCHEMBL4295771

CN(C)C(=O)c1n[nH]c2ccc(I)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.47
JAK1 P23458 1/20 0.45
FLT3 P36888 1/20 0.43
PRKAG1 P54619 1/20 0.41
PRKAA1 Q13131 1/20 0.41
PRKAB1 Q9Y478 1/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 1/20 0.39
DYRK1A Q13627 6/20 0.39
KDM4E B2RXH2 3/20 0.38
YTHDC1 Q96MU7 1/20 0.38
STAT3 P40763 1/20 0.38
HIF1A Q16665 1/20 0.38
HAO1 Q9UJM8 1/20 0.37
PAK1 Q13153 1/20 0.37
WNT1 P04628 2/20 0.37
CLK2 P49760 1/20 0.36
CLK3 P49761 1/20 0.36
GABRA1 P14867 2/20 0.35
GABRG2 P18507 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909088 0.90 PRKAG1 (0.40) CDC7JAK1FLT3PRKAG1PRKAA1
SCHEMBL11970852 0.88 JAK1 (0.54) CDC7JAK1FLT3MAPK1TSHR
SCHEMBL4437501 0.86 PRKAA1 (0.43) CDC7JAK1FLT3PRKAG1PRKAA1
SCHEMBL16910325 0.83 CDC7 (0.48) CDC7JAK1FLT3PRKAG1PRKAA1
SCHEMBL21496911 0.82 PDPK1 (0.54) CDC7JAK1FLT3PRKAG1PRKAA1
SCHEMBL953396 0.81 PRKAG1 (0.55) PRKAG1PRKAA1PRKAB1HAO1
SCHEMBL6195016 0.80 DYRK1A (0.44) JAK1PRKAG1PRKAA1PRKAB1MAPK1
SCHEMBL1141823 0.79 KDM4E (0.63) CDC7FLT3PRKAG1PRKAA1PRKAB1
SCHEMBL19001429 0.79 YTHDC1 (0.63) JAK1FLT3DYRK1AYTHDC1PAK1
SCHEMBL1596970 0.78 FLT3 (0.64) CDC7JAK1FLT3TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885JAK1 73/4885FLT3 312/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885JAK1 73/4885FLT3 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.